YOLFTbeta
Vicore Pharma Holding AB (publ)

Vicore Pharma Holding AB (publ)

VICO · ST · Healthcare / Biotechnology

10.72SEK-0.26 (-2.37%)

Price History

Full chart

Market Stats

Previous Close10.98
Open10.94
Day Range10.64 – 11.12
52-Week Range8.62 – 18.24
Volume869.85K
Market Cap2.52B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.91
Dividend Yield0.00%
Beta0.09
50-Day Avg10.64
200-Day Avg10.90

About

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. It has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Ahmed S. Mousa J.D.
  • Employees46
  • HeadquartersKornhamnstorg 53, Stockholm, Sweden, 111 27, Sweden
  • Websitehttps://www.vicorepharma.com

Leadership

  • Mr. Ahmed S. Mousa J.D.Chief Executive Officer · b. 1984
  • Mr. Hans Jeppsson Ph.D.Chief Financial Officer
  • Mr. Mikael NygårdChief Operating Officer
  • Ms. Helen BarkerChief Technology Officer
  • Dr. Rob Slack Ph.D.Chief Scientific Officer
  • Ms. Nina CarlenChief Administrative Officer
  • Mr. Karam HijjiGeneral Counsel
  • Mr. Jason HoffmanVP & Head of Human Resources
  • Ms. Johanna Grans Ph.D.Head of Non-Clinical Development
  • Mr. Jimmie HofmanChief Business Officer

Financials

Income Statement

Currency: SEK2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue3.31K3.31M1.57M840.00K852.00K932.00K508.00K00000109.35M3.82M
Growth (%)-+99628.42%-52.47%-46.53%+1.43%+9.39%-45.49%-100.00%------96.51%
Cost of Revenue2.98K-720.00K-720.00K-816.00K-1.22M-2.65M21.76M1.34M3.54M3.60M3.61M3.42M--
Gross Profit3394.03M2.29M1.66M2.07M3.58M-21.25M-1.34M-3.54M-3.60M-3.61M-3.42M109.35M3.82M
Gross Margin10.23%121.79%145.83%197.14%243.31%383.80%-4182.68%-----100.00%100.00%
Operating Expense2.12K7.02M7.63M6.20M8.72M16.37M23.03M92.68M146.00M291.22M287.11M318.08M303.54M458.26M
Operating Income-1.78K-3.00M-5.34M-4.54M-6.65M-12.79M-44.28M-94.01M-149.54M-294.82M-290.73M-321.51M-194.19M-454.44M
Operating Margin-53.74%-90.62%-339.91%-540.83%-780.40%-1372.64%-8716.54%------177.59%-11905.82%
EBITDA-1.74K-1.46M-4.93M-4.54M-6.65M-23.81M-38.25M-92.51M-143.77M-289.82M-286.20M-317.47M-166.64M-477.41M
EBITDA Margin-52.60%-44.21%-313.69%-540.12%-780.05%-2555.15%-7528.94%------152.40%-12507.57%
Net Income-3.16K-1.60M13.69M-4.57M-6.65M-12.86M-21.68M-93.08M-146.86M-296.48M-288.42M-310.94M-168.63M-477.47M
Net Income Margin-95.29%-48.50%871.23%-544.05%-780.75%-1379.29%-4267.91%------154.22%-12509.14%
R&D---3.87M12.26M17.55M20.46M67.05M142.02M271.81M249.97M272.87M249.26M390.35M
R&D as % of Total Revenue---460.48%1438.62%1883.58%4028.15%-----227.96%10226.57%
Interest Expense-219.00K105.00K27.00K3.00K62.00K352.00K27.00K6.00K11.00K8.00K358.00K8.00K50.34M
Interest Expense % of Total Revenue-6.63%6.68%3.21%0.35%6.65%69.29%-----0.01%1318.97%

Balance Sheet

Currency: SEK2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets38.34K50.98M59.37M89.22M81.65M119.53M301.60M341.11M406.51M451.17M338.01M497.84M1.20B1.22B
Total Liabilities12.09K10.97M5.67M7.29M6.05M6.56M16.16M19.51M52.00M67.85M48.92M42.45M73.78M124.16M
Total Equity26.25K40.01M53.70M81.93M75.60M112.97M285.44M321.60M354.51M383.32M289.08M455.39M1.13B1.10B
Cash3.71K14.03M1.71M25.18M4.27M24.02M224.69M187.59M248.62M294.20M256.80M333.62M1.16B578.15M
Total Debt-7.10M1.50M----190.00K140.00K320.00K65.00K---
Net Debt-3.71K-6.92M-210.00K-25.18M-4.27M-24.02M-224.69M-187.40M-248.48M-293.88M-256.74M-333.62M-1.16B-578.15M

Cash Flow

Currency: SEK2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.67K-1.79M-2.83M-3.68M-7.25M-7.71M-33.04M-87.00M-119.94M-265.17M-299.92M-249.58M-164.95M-374.44M
Investing Cash Flow-4.53K-2.87M-2.39M-5.66M-13.98M-22.78M15.03M-77.15M4.00M-7.00M74.00M-144.46M149.04M-601.81M
Financing Cash Flow-14.98M-7.10M32.80M319.00K50.24M218.68M127.04M176.97M318.18M187.04M470.86M834.06M430.54M
Capital Expenditure3109.49M5.66M13.48M20.23M2.00M147.00K3.00M03.00M199.04M64.81M374.44M
Free Cash Flow-1.70K-1.79M-12.31M-9.34M-20.73M-27.94M-35.04M-87.15M-122.94M-265.17M-302.92M-448.62M-164.95M-375.74M
FCF to OCF101.86%100.00%435.93%253.64%285.86%362.60%106.05%100.17%102.50%100.00%101.00%179.75%100.00%100.35%

Earnings

Report DateApr 15, 2016Jul 8, 2016Oct 13, 2016Feb 24, 2017May 10, 2017Aug 24, 2017Oct 19, 2017Feb 21, 2018May 8, 2018Aug 24, 2018Nov 8, 2018Mar 15, 2019May 15, 2019Aug 23, 2019Nov 8, 2019Feb 28, 2020May 5, 2020Aug 26, 2020Nov 6, 2020Feb 26, 2021May 5, 2021Aug 26, 2021Nov 4, 2021Feb 25, 2022May 5, 2022Aug 25, 2022Nov 3, 2022Feb 28, 2023May 4, 2023Aug 24, 2023Nov 2, 2023Feb 28, 2024May 3, 2024Aug 22, 2024Nov 5, 2024Feb 27, 2025May 6, 2025Aug 22, 2025Nov 5, 2025Feb 27, 2026May 6, 2026Aug 21, 2026
EPS Estimate-----0.00---------0.62-0.51-0.56-0.53-0.89-0.49-0.58-1.76-1.77-1.51-1.22-0.92-1.51-0.81-0.78-0.73-0.65-0.590.28---0.36-0.41-0.46-0.46-0.46-0.48-0.45
EPS Actual-0.14-0.10-0.11-0.13-0.14-0.15-0.09-0.870.240.28-0.27-0.42-0.40-0.63-0.54-0.60-0.56-0.48-0.65-0.96-0.76-0.98-1.36-1.12-1.30-0.92-1.12-0.83-0.81-0.85-0.58-1.000.28-0.50-0.54-0.39-0.48-0.49-0.48-0.54-0.39-0.51
Surprise--------------12.90%-17.65%0.00%9.43%26.97%-95.92%-31.03%44.32%23.16%25.83%-6.66%0.23%25.83%-1.96%-3.85%-16.44%10.77%-69.49%1.39%---8.08%-17.07%-6.52%-4.35%-17.39%18.75%-13.33%
TimingPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap2.52B
Enterprise Value1.86B
Trailing P/E0.00
Forward P/E0.00
Price / Sales631.83
Price / Book3.24
EPS-1.91
Book Value3.03
Revenue (TTM)3.99M
Gross Profit (TTM)3.99M
EBITDA-452.20M
Profit Margin0.00%
Operating Margin-6762.49%
Return on Equity-56.99%
Return on Assets-34.35%
Shares Outstanding281.64M
Shares Float198.58M
Beta0.09
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Sep 17, 202437:36
  • Sep 14, 2018396:347